|
1
|
Bielack SS, Kempf-Bielack B, Delling G, et
al: Prognostic factors in high-grade osteosarcoma of the
extremities or trunk: an analysis of 1,702 patients treated on
neoadjuvant cooperative osteosarcoma study group protocols. J Clin
Oncol. 20:776–790. 2002. View Article : Google Scholar
|
|
2
|
Whelan JS, Jinks RC, McTiernan A, et al:
Survival from high-grade localised extremity osteosarcoma: combined
results and prognostic factors from three European Osteosarcoma
Intergroup randomised controlled trials. Ann Oncol. Oct
19–2011.(Epub ahead of print). View Article : Google Scholar
|
|
3
|
Bacci G, Longhi A, Versari M, Mercuri M,
Briccoli A and Picci P: Prognostic factors for osteosarcoma of the
extremity treated with neoadjuvant chemotherapy: 15-year experience
in 789 patients treated at a single institution. Cancer.
106:1154–1161. 2006.PubMed/NCBI
|
|
4
|
Ferrari S, Smeland S, Mercuri M, et al:
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose
methotrexate, cisplatin, and doxorubicin for patients with
localized osteosarcoma of the extremity: a joint study by the
Italian and Scandinavian Sarcoma Groups. J Clin Oncol.
23:8845–8852. 2005. View Article : Google Scholar
|
|
5
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsutsumi S, Yanagawa T, Shimura T, et al:
Regulation of cell proliferation by autocrine motility
factor/phosphoglucose isomerase signaling. J Biol Chem.
278:32165–32172. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Silletti S, Watanabe H, Hogan V, Nabi IR
and Raz A: Purification of B16-F1 melanoma autocrine motility
factor and its receptor. Cancer Res. 51:3507–3511. 1991.PubMed/NCBI
|
|
8
|
Watanabe H, Kanbe K and Chigira M:
Differential purification of autocrine motility factor derived from
a murine protein-free fibrosarcoma. Clin Exp Metastasis.
12:155–163. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Funasaka T, Haga A, Raz A and Nagase H:
Tumor autocrine motility factor is an angiogenic factor that
stimulates endothelial cell motility. Biochem Biophys Res Commun.
284:1116–1125. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Funasaka T, Haga A, Raz A and Nagase H:
Autocrine motility factor secreted by tumor cells upregulates
vascular endothelial growth factor receptor (Flt-1) expression in
endothelial cells. Int J Cancer. 101:217–223. 2002. View Article : Google Scholar
|
|
11
|
Tsutsumi S, Hogan V, Nabi IR and Raz A:
Overexpression of the autocrine motility factor/phosphoglucose
isomerase induces transformation and survival of NIH-3T3
fibroblasts. Cancer Res. 63:242–249. 2003.PubMed/NCBI
|
|
12
|
Haga A, Funasaka T, Niinaka Y, Raz A and
Nagase H: Autocrine motility factor signaling induces tumor
apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome
expression. Int J Cancer. 107:707–714. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Watanabe H, Takehana K, Date M, Shinozaki
T and Raz A: Tumor cell autocrine motility factor is the
neuroleukin/phosphohexose isomerase polypeptide. Cancer Res.
56:2960–2963. 1996.PubMed/NCBI
|
|
14
|
Faik P, Walker JI, Redmill AA and Morgan
MJ: Mouse glucose-6-phosphate isomerase and neuroleukin have
identical 3′ sequences. Nature. 332:455–457. 1988.
|
|
15
|
Niinaka Y, Paku S, Haga A, Watanabe H and
Raz A: Expression and secretion of neuroleukin/phosphohexose
isomerase/maturation factor as autocrine motility factor by tumor
cells. Cancer Res. 58:2667–2674. 1998.PubMed/NCBI
|
|
16
|
Yanagawa T, Watanabe H, Takeuchi T,
Fujimoto S, Kurihara H and Takagishi K: Overexpression of autocrine
motility factor in metastatic tumor cells: possible association
with augmented expression of KIF3A and GDI-beta. Lab Invest.
84:513–522. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yanagawa T, Funasaka T, Tsutsumi S, Raz T,
Tanaka N and Raz A: Differential regulation of phosphoglucose
isomerase/autocrine motility factor activities by protein kinase
CK2 phosphorylation. J Biol Chem. 280:10419–10426. 2005. View Article : Google Scholar
|
|
18
|
Baumann M, Kappl A, Lang T, Brand K,
Siegfried W and Paterok E: The diagnostic validity of the serum
tumor marker phosphohexose isomerase (PHI) in patients with
gastrointestinal, kidney, and breast cancer. Cancer Invest.
8:351–356. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Filella X, Molina R, Jo J, Mas E and
Ballesta AM: Serum phosphohexose isomerase activities in patients
with colorectal cancer. Tumour Biol. 12:360–367. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bodansky O: Serum phosphohexose isomerase
in cancer. II. As an index of tumor growth in metastatic carcinoma
of the breast. Cancer. 7:1200–1226. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Patel PS, Raval GN, Rawal RM, et al:
Comparison between serum levels of carcinoembryonic antigen, sialic
acid and phosphohexose isomerase in lung cancer. Neoplasma.
42:271–274. 1995.PubMed/NCBI
|
|
22
|
Dobashi Y, Watanabe H, Matsubara M, et al:
Autocrine motility factor/glucose-6-phosphate isomerase is a
possible predictor of metastasis in bone and soft tissue tumours. J
Pathol. 208:44–53. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Niinaka Y, Harada K, Fujimuro M, et al:
Silencing of autocrine motility factor induces
mesenchymal-to-epithelial transition and suppression of
osteosarcoma pulmonary metastasis. Cancer Res. 70:9483–9493. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Issels RD, Lindner LH, Verweij J, et al:
Neo-adjuvant chemotherapy alone or with regional hyperthermia for
localised high-risk soft-tissue sarcoma: a randomised phase 3
multicentre study. Lancet Oncol. 11:561–570. 2010. View Article : Google Scholar
|
|
25
|
Alcaide M, Ramírez-Santillán C, Feito MJ,
et al: In vitro evaluation of glass-glass ceramic
thermoseed-induced hyperthermia on human osteosarcoma cell line. J
Biomed Mater Res A. 100:64–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Trieb K, Blahovec H and Kubista B: Effects
of hyperthermia on heat shock protein expression, alkaline
phosphatase activity and proliferation in human osteosarcoma cells.
Cell Biochem Funct. 25:669–672. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shui C and Scutt A: Mild heat shock
induces proliferation, alkaline phosphatase activity, and
mineralization in human bone marrow stromal cells and Mg-63 cells
in vitro. J Bone Miner Res. 16:731–741. 2001. View Article : Google Scholar
|
|
28
|
Shido Y, Nishida Y, Suzuki Y, Kobayashi T
and Ishiguro N: Targeted hyperthermia using magnetite cationic
liposomes and an alternating magnetic field in a mouse osteosarcoma
model. J Bone Joint Surg Br. 92:580–585. 2010. View Article : Google Scholar
|
|
29
|
Bagatell R, Beliakoff J, David CL, Marron
MT and Whitesell L: Hsp90 inhibitors deplete key anti-apoptotic
proteins in pediatric solid tumor cells and demonstrate synergistic
anticancer activity with cisplatin. Int J Cancer. 113:179–188.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shin KD, Lee MY, Shin DS, et al: Blocking
tumor cell migration and invasion with biphenyl isoxazole
derivative KRIBB3, a synthetic molecule that inhibits Hsp27
phosphorylation. J Biol Chem. 280:41439–41448. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yokota S, Kitahara M and Nagata K:
Benzylidene lactam compound, KNK437, a novel inhibitor of
acquisition of thermotolerance and heat shock protein induction in
human colon carcinoma cells. Cancer Res. 60:2942–2948.
2000.PubMed/NCBI
|
|
32
|
Bagatell R, Gore L, Egorin MJ, et al:
Phase I pharmacokinetic and pharmacodynamic study of
17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with
recurrent or refractory solid tumors: a pediatric oncology
experimental therapeutics investigators consortium study. Clin
Cancer Res. 13:1783–1788. 2007. View Article : Google Scholar
|
|
33
|
Koga F, Kihara K and Neckers L: Inhibition
of cancer invasion and metastasis by targeting the molecular
chaperone heat-shock protein 90. Anticancer Res. 29:797–807.
2009.PubMed/NCBI
|
|
34
|
Sato T, Sawaji Y, Matsui N, et al: Heat
shock suppresses membrane type 1-matrix metalloproteinase
production and progelatinase A activation in human fibrosarcoma
HT-1080 cells and thereby inhibits cellular invasion. Biochem
Biophys Res Commun. 265:189–193. 1999. View Article : Google Scholar
|
|
35
|
Funasaka T, Hu H, Yanagawa T, Hogan V and
Raz A: Down-regulation of phosphoglucose isomerase/autocrine
motility factor results in mesenchymal-to-epithelial transition of
human lung fibrosarcoma cells. Cancer Res. 67:4236–4243. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Funasaka T, Hogan V and Raz A:
Phosphoglucose isomerase/autocrine motility factor mediates
epithelial and mesenchymal phenotype conversions in breast cancer.
Cancer Res. 69:5349–5356. 2009. View Article : Google Scholar
|
|
37
|
Kugler W, Breme K, Laspe P, et al:
Molecular basis of neurological dysfunction coupled with haemolytic
anaemia in human glucose-6-phosphate isomerase (GPI) deficiency.
Hum Genet. 103:450–454. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yanagawa T, Funasaka T, Tsutsumi S, Hu H,
Watanabe H and Raz A: Regulation of phosphoglucose
isomerase/autocrine motility factor activities by the
poly(ADP-ribose) polymerase family-14. Cancer Res. 67:8682–8689.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nakano H, Tateishi A, Miki H, et al:
Hyperthermic isolated regional perfusion for the treatment of
osteosarcoma in the lower extremity. Am J Surg. 178:27–32. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Williams RR, Hassan-Walker AF, Lavender
FL, Morgan M, Faik P and Ragoussis J: The minisatellite of the
GPI/AMF/NLK/MF gene: interspecies conservation and transcriptional
activity. Gene. 269:81–92. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Funasaka T, Yanagawa T, Hogan V and Raz A:
Regulation of phosphoglucose isomerase/autocrine motility factor
expression by hypoxia. FASEB J. 19:1422–1430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Khalil AA, Kabapy NF, Deraz SF and Smith
C: Heat shock proteins in oncology: diagnostic biomarkers or
therapeutic targets? Biochim Biophys Acta. 1816:89–104.
2011.PubMed/NCBI
|
|
43
|
Jego G, Hazoumé A, Seigneuric R and
Garrido C: Targeting heat shock proteins in cancer. Cancer Lett.
Nov 13–2010.(Epub ahead of print).
|
|
44
|
Uozaki H, Horiuchi H, Ishida T, Iijima T,
Imamura T and Machinami R: Overexpression of resistance-related
proteins (metallothioneins, glutathione-S-transferase pi, heat
shock protein 27, and lung resistance-related protein) in
osteosarcoma. Relationship with poor prognosis. Cancer.
79:2336–2344. 1997. View Article : Google Scholar
|
|
45
|
Moon A, Bacchini P, Bertoni F, et al:
Expression of heat shock proteins in osteosarcomas. Pathology.
42:421–425. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Têtu B, Lacasse B, Bouchard HL, Lagacé R,
Huot J and Landry J: Prognostic influence of HSP-27 expression in
malignant fibrous histiocytoma: a clinicopathological and
immunohistochemical study. Cancer Res. 52:2325–2328.
1992.PubMed/NCBI
|
